Tucker Coston, M.D.

@BHuffmanMD #TumorBoardTuesday Comprehensive PANEL-based testing for all metastatic #CRCSM especially the #AYACSM. Would easily miss events like this case since the report here would just say MSS/pMMR RAS/RAF/HER2 status without ever the opportunity to get #immunotherapy. 🧬POL-E

@ShimaghavimiMD @drjasonstarr @TumorBoardTues @DrBonillaOnc @drjasonstarr, do you have the patient's NGS data handy? I don't want to tell you the wrong thing!

@drjasonstarr @TumorBoardTues @DrBonillaOnc @TuckerCoston Can we have the location and type of mutation

#TumorBoardTuesday B/C of the Olympics, I'm so tempted to make some sort of POLE vaulting joke🤔 But I won't minimize what will be an outstanding🗣️on POLE mutations in CRC, led by @drjasonstarr & @TuckerCoston 📢 Join us Tuesday, 07/27/21🕗8-9PM EST and⚖️in and give us your💭

...from the ongoing discussion re: POLE mutations in CRC!

@BHuffmanMD @pashtoonkasi @MPishvaian @drjasonstarr @TumorBoardTues @VanMorrisMD Thanks for linking this in for us! Great to see you here, Dr. Huffman 🤩

@pashtoonkasi @MPishvaian @drjasonstarr @TumorBoardTues @VanMorrisMD For anyone like me who didn’t know what the COBRA 🐍 trial was, here’s the link to it. Interesting study! #TumorBoardTuesday clinicaltrials.gov/ct2/show/NCT04…

@ShimaghavimiMD @drjasonstarr @TumorBoardTues Laser-targeted reference! It's like the paper was written for this patient. Thanks for sharing!

@drjasonstarr @TumorBoardTues pubmed.ncbi.nlm.nih.gov/32859741/

Tune in for the #TumorBoardTuesday! Will be live posting the case for discussion and learning

Excited for #TumorBoardTuesday this evening! Dr. Starr presenting a case of ours that highlights POLE-mutated colorectal adenocarcinoma.